Back to state act
Back to state act
Description
On 19 December 2025, the U.S. Administration announced an agreement with Novartis. Under the agreement, Novartis expects to receive three years of relief from the potential Section 232 pharmaceutical ...
Intervention Details
Intervention Type
Local operations incentive
MAST Chapter
I: Trade-related investment measures
Implementation date
No implementation date
Revocation date
No revocation date
Implementation level
National
Affected flow
Inward
Announced as temporary
No
Eligible firms
firm-specific
Affected Sectors
Affected Products
See all
This intervention is not part of any Thread yet.